Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
32
datasets available to search
ShareScore release 0.9.0
Dataset results
32 results for “DMT”
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
ClinicalTrials.gov study NCT02861014. IPD Sharing: Not stated. Countries: 17. Publications: 1.
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
ClinicalTrials.gov study NCT02637856. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
ClinicalTrials.gov study NCT06816667. IPD Sharing: YES. Countries: 1. Publications: 1.
Neural and subjective effects of inhaled DMT in natural settings
<p>Raw EEG data (DMT, eyes open and eyes closed) and psychometric scales for the 35 participants of "Neural and subjective effects of inhaled DMT in natural settings".</p>
GEOLAB - Transnational Access project JELLYFISh - Field testing of Medusa DMT
<p>The project <strong>JELLYFISh</strong> <em>(<strong>A Just-released innovativE in-situ soiL testing technoLogY (Medusa DMT/SDMT) For enhancing the resilience of the critical InfraStructure in Europe</strong></em><em>)</em> aims to contribute to the advancement of knowledge on geotechnical characterization of soil deposits commonly encountered in risk-sensitive areas (intermediate soils, soft clays, quick clays, loose sands), often associated to multiple geo-hazards that may negatively interact with CI networks. Improvements in geotechnical approaches to analysis and mitigation of such hazards, in order to increase the resilience of the CI, rely significantly on enhanced characterization of soil behaviour.</p> <p> </p> <p>The methodology employed for this purpose is the innovative Medusa (S)DMT in-situ soil testing technology. The research project is based on an extensive experimental in-situ testing program with Medusa (S)DMT in different soil types at benchmark Geo-Test Sites (NGTS), part of the research infrastructure managed by the NGI. A comprehensive high-quality soil database, including data from field and laboratory tests, published articles and reports, is available from NGI. The sites (target soil types) that were recognized of specific interest for this project are Halden (silt), Onsøy (soft clay), Tiller-Flotten (quick clay), and Øysand (sand).</p> <p>The project benefits from the collaboration of users from industry and academia, making use of the access to the GEOLAB facility to test and implement new technology solutions. The relevant Technology Readiness Level (TRL) of the project is in the group (TRL4-7), pertaining to technology development of solutions to enhance the resilience of the CI.</p> <p> </p> <p>The main objectives of the project and their significance in terms of innovation / advancement of knowledge are:</p> <ul> <li>Innovative approach for characterizing the in-situ behaviour of intermediate soils by Medusa DMT tests at variable pressurization/penetration rates, in combination with available data from variable-rate CPTU tests.</li> </ul> <ul> <li>Advancement in soil property characterization of soft clay deposits by innovative in-situ testing procedures (e.g., in-situ horizontal stress / coefficient of earth pressure at rest <em>K</em><sub>0</sub> from continuous measurement of total horizontal pressure during Medusa DMT penetration).</li> <li>Novel approach for mapping quick clay layers by innovative in-situ testing procedures (continuous measurement of total horizontal pressure during Medusa DMT penetration).</li> <li>Improvement of DMT interpretation in sand, including the investigation of the effect of fines content and partial drainage (to be introduced into DMT-based simplified methods for liquefaction assessment).</li> </ul>
Single and Repeat Doses of DMT in Healthy Subjects
ClinicalTrials.gov study NCT05559931. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
ClinicalTrials.gov study NCT04673383. IPD Sharing: NO. Countries: 1. Publications: 2.
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
ClinicalTrials.gov study NCT05698095. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
ClinicalTrials.gov study NCT03368664. IPD Sharing: YES. Countries: 7. Publications: 0.
Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study
ClinicalTrials.gov study NCT00722943. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
ClinicalTrials.gov study NCT04716335. IPD Sharing: NO. Countries: 1. Publications: 2.
Safety and Tolerability of DMT in Healthy Adults
ClinicalTrials.gov study NCT05901012. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
ClinicalTrials.gov study NCT06094907. IPD Sharing: NO. Countries: 1. Publications: 2.
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
ClinicalTrials.gov study NCT04788615. IPD Sharing: YES. Countries: 4. Publications: 0.
Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders
ClinicalTrials.gov study NCT02304796. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
ClinicalTrials.gov study NCT06812221. IPD Sharing: YES. Countries: 1. Publications: 0.
The 'Wearing Off' Effect of DMT
ClinicalTrials.gov study NCT05627271. IPD Sharing: NO. Countries: 1. Publications: 0.
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects
ClinicalTrials.gov study NCT05829603. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
ClinicalTrials.gov study NCT06051721. IPD Sharing: NO. Countries: 1. Publications: 0.
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)
ClinicalTrials.gov study NCT05695495. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.